<DOC>
	<DOC>NCT01140893</DOC>
	<brief_summary>The purpose of this study is to determine whether exenatide is effective to improve glycemic control among type 2 diabetic patients treated by insulin pump therapy.</brief_summary>
	<brief_title>Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Men or women aged 35 to 70 Type 2 diabetes diagnosed for at least 12 months, according the criteria of the American Diabetes Association : presence of classic symptoms of diabetes mellitus with unequivocal elevation of plasma glucose (2hour postprandial or random glucose &gt;200 mg/dL) or fasting plasma glucose elevation on more than 1 occasion &gt; 125 mg/dL or patient currently undergoing pharmacological and/or nonpharmacological treatment for diabetes mellitus CSII treatment using a rapid analog for at least 6 month (CSII being initiated in patients with HbA1c &gt; 8 % despite a wellconducted MDI trial using a 2 to 5 daily injection regimen) HbA1c ≥ 7,5% and ≤ 10 % BMI ≥ 25 and ≤ 45 Stable body weight (≤10% variation) during the 3 last months Type 1 diabetes assessed by positive antiGAD65 or antiinsulin or antiIA2 antibodies Monogenic diabetes (MODY, mitochondrial diabetes…) Current treatment with OHA (OHA ought to be interrupted at least two months prior to inclusion in the study) Current treatment specifically addressed for weight lost (orlistat, sibutramine, rimonabant may be interrupted at least 3 months prior to inclusion in the study) Use of corticosteroid therapy for more than 10 days within the 3past months, or patient who ought to be treated by corticosteroid during the study period Clinically significant hepatic disease Documented gastroparesis, or current use of drugs that directly affect gastrointestinal motility, or any significant abdominal disease that may increase the risk of adverse gastrointestinal effects induced by exenatide Kidney failure (MDRD less than 50 ml/min) Pregnancy/breastfeeding Any social and/or mental condition rendering the subject unable to understand the scope and possible consequences of the study Concurrent enrolment in another clinical trial Geographically inaccessible for followup visits required by protocol</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>CSII</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Double Blind Placebo Controlled Study</keyword>
</DOC>